Nanoform launches next-generation STARMAP[®] v2.0, the AI-based drug candidate selection tool for CESS[® ]
Press release Nanoform Finland Plc March 22, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform launches next-generation STARMAP[®] v2.0, the AI-based drug candidate selection tool for CESS[® ] Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has today launched the next generation of its STARMAP[® ]AI (artificial intelligence) platform, v2.0. The technology utilizes sparse-data AI to augment experimental results from its CESS[®] nanoparticle engineering process with detailed expert knowledge, allowing reliable